A 18F‐Labeled Fluorobutyl‐Substituted Spirocyclic Piperidine Derivative as a Selective Radioligand for PET Imaging of Sigma1 Receptors

A 18F‐Labeled Fluorobutyl‐Substituted Spirocyclic Piperidine Derivative as a Selective Radioligand for PET Imaging of Sigma1 Receptors
复制标题

18F 标记的氟丁基取代的螺环哌啶衍生物作为 Sigma1 受体 PET 成像的选择性放射性配体

DOI:
--
复制
发表时间:
2011
期刊:
影响因子:
3.4
通讯作者:
P. Brust
P. Brust
中科院分区:
医学4区
文献类型:
--
作者:
Aurélie Maisonial;Eva Große Maestrup;S. Fischer;A. Hiller;M. Scheunemann;C. Wiese;D. Schepmann;J. Steinbach;W. Deuther;B. Wünsch;P. Brust

文献摘要

参考文献

被引文献

相似文献

在本研究中,我们合成并评估了一种新的螺环哌啶衍生物 3,其含有 4-氟丁基侧链,作为 σ1 受体神经成像的 PET 放射性配体。在体外,化合物 3 对 σ1 受体表现出高亲和力 (Ki=1.2 nM) 以及高选择性。 [18F]3放射合成是由相应的甲苯磺酸盐前体进行的,具有高放射化学产率(45–51%)、纯度(>98%)和比活性(>201 GBq μmol−1)。验证了CD-1小鼠脑内[18F]3的代谢稳定性,未观察到外周放射性代谢物渗透至脑组织。离体放射自显影结果显示,大脑中[18F]3的分布与σ1受体密度高的区域相对应。面部核中确定了最高的区域特异性总与非特异性比率(4.00)。生物分布研究表明,[18F]3 的大脑摄取水平快速且高(注射后 5 分钟,每克 2.2% ID)。预先给予氟哌啶醇可显着抑制大脑和 σ1 受体表达器官对 [18F]3 的摄取,进一步证实了体内靶点特异性。
In this study, we synthesized and evaluated a new spirocyclic piperidine derivative 3, containing a 4‐fluorobutyl side chain, as a PET radioligand for neuroimaging of σ1 receptors. In vitro, compound 3 displayed high affinity for σ1 receptors (Ki=1.2 nM) as well as high selectivity. [18F]3 radiosynthesis was performed from the corresponding tosylate precursor, with high radiochemical yield (45–51 %), purity (>98 %), and specific activity (>201 GBq μmol−1). Metabolic stability of [18F]3 in the brain of CD‐1 mice was verified, and no penetration of peripheral radiometabolites into the cerebral tissue was observed. Results of ex vivo autoradiography revealed that the distribution of [18F]3 in the brain corresponded to regions with high σ1 receptor density. The highest region‐specific total‐to‐nonspecific ratio was determined in the facial nucleus (4.00). Biodistribution studies indicated rapid and high levels in brain uptake of [18F]3 (2.2 % ID per gram at 5 min p.i.). Pre‐administration of haloperidol significantly inhibited [18F]3 uptake into the brain and σ1 receptor‐expressing organs, further confirming in vivo target specificity.
DOI: 10.1016/j.tips.2010.08.007
发表时间: 2010-12
影响因子: 13.8
作者:
Su TP;Hayashi T;Maurice T;Buch S;Ruoho AE
通讯作者: Ruoho AE
DOI: 10.1006/bbrc.1996.1842
发表时间: 1996-12-13
影响因子: 3.1
作者:
Kekuda, R;Prasad, PD;Ganapathy, V
通讯作者: Ganapathy, V
DOI: 10.1016/j.pharmthera.2010.04.003
发表时间: 2010-09
影响因子: 13.5
作者:
Fishback, James A.;Robson, Matthew J.;Xu, Yan-Tong;Matsumoto, Rae R.
通讯作者: Matsumoto, Rae R.
DOI: 10.1016/j.pharmthera.2009.07.001
发表时间: 2009-11
影响因子: 13.5
作者:
Maurice T;Su TP
通讯作者: Su TP
DOI: 10.1016/0024-3205(94)90051-5
发表时间: 1994
期刊: Life sciences
影响因子: 6.1
作者:
J. Musachio;U. Scheffel;M. Stathis;H. Ravert;W. B. Mathews;R. Dannals
通讯作者: J. Musachio;U. Scheffel;M. Stathis;H. Ravert;W. B. Mathews;R. Dannals